ProJect Pharmaceutics And Technische Universitat Munchen-Spin-Off ImevaX Announce Agreement On Development Of Pharmaceutical Formulation For IMX101

Published: Dec 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Munich/Martinsried, Germany, December 2, 2013 / B3C newswire / -ProJect Pharmaceutics announces that it has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent vaccine, making the formulation development particularly challenging.

The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.

Promising formulation candidates have successfully been evaluated and are continuously optimized within the development program since its launch in mid 2013.

Financial terms of the current agreement are not disclosed.

About ProJect Pharmaceutics

ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and cytotoxic molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying innovative concepts of pharmaceutical development.

ProJect Pharmaceutics makes sure that investigational products as well as new presentations of registered drugs are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.

About ImevaX

As part of the GO-Bio start up program of the German Ministry of Research and Education (BMBF), the TUM-based Spin-off project ImevaX from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institue for Medicinal Microbiology, Immunology and Hygiene, develops highly specific vaccines against pathogens that cause chronic infectious diseases. Its technology identifies immune modulatory bacterial factors that are then used to develop effective vaccines against infections of global relevance. ImevaX is planned to be founded as a biotech company in 2014.


ProJect Pharmaceutics GmbH

Fraunhoferstraße 22

D-82152 Martinsried

+49 (0) 89 452289700

Dr. Andreas Schütz:

Klaus Hellerbrand:


Medizinische Mikrobiologie, Immunologie und Hygiene

Trogerstraße 30

D-81675 München

+49 (0) 89 4140 2477

Prof. Dr. Markus Gerhard:

Help employers find you! Check out all the jobs and post your resume.

Back to news